Carlsmed Inc [Ordinary Shares]

Carlsmed reported Q1 2026 revenue growth of 58% to $16.1 million and an improved gross margin of 77.1% (+220 basis points). Operating expenses rose 62% to $21.7 million, and the net loss widened to $8.7 million. The stock fell 2.31% after hours; investors are concerned about higher spending despite strong market acceptance. The company holds $97.1 million in cash and plans a full commercial launch of its bilateral lumbar fusion platform in Q4 2026, aiming for further revenue growth and improved adjusted EBITDA. » More on de.investing.com

Carlsmed posted an 86% revenue increase in 2025 to $50.5 million and improved gross margin to 75.3%. Operating expenses rose 55% to $68.6 million, leading to a GAAP net loss of $29.6 million and adjusted EBITDA of -$28.4 million. The company raised over $100 million in its July 2025 IPO and expects 2026 revenue of around $70.17 million with stable gross margins; management sees a path to profitability through economies of scale. The stock fell 3.83% in after-hours trading. » More on de.investing.com

A retrospective cohort study in the Global Spine Journal shows that personalized "aprevo" interbody implants from Carlsmed reduce the two‑year revision rate for complex spinal deformities from 16.6% to 4.3% (relative reduction 74%). The study compared 115 patients treated with "aprevo" to a 997‑patient control cohort from the International Spine Study Group. Carlsmed combines AI‑driven 3D planning with patient‑specific implants; the company’s stock recently fell 9.17% despite the clinical data, with a market valuation of $321.4 million. » More on de.investing.com